Microport Scientific Corp. · HKEX:853
Microport Scientific — FY2021 Earnings Presentation
30 slides from Microport Scientific's earnings presentation, Mar 31, 2022
Slide 1: MicroPort Scientific Corporation 2021 Annual Results
MicroPort Scientific Corporation 2021 Annual Results March 2022
Slide 2: Disclaimer
2021 Annual Results Disclaimer 31 March 2022 This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no pa
Slide 3: Contents
Contents 1 Company Highlights 2 Business Review 3 Financial Review 4 Outlook 5 Appendix – Financial Statements
Slide 4: Ambitious pursuit of innovation for 24 consecutive years
2021 Annual Results Ambitious pursuit of innovation for 24 consecutive years 31 March 2022 Core Business Total cardio solutions Other sectors covering main clinical specialties Global leading medical devices Partnerships with global Unswervingly company Uncompromising in Industry leading leading KOL
Slide 5: Total health solutions covering most of the major clinical specialties
Total health solutions covering most of the major clinical specialties Total Cardio Solutions Cardiovascular CRM Top 2 global player & Top 1 Chinese player One of the only 5 multi-national players & Top 1 DES no. of implantation exceeded 7.5mn units, Chinese player covering ~40 countries around the
Slide 6: Outstanding performance amid COVID across all segments
2021 Annual Results Outstanding performance amid COVID across all segments 31 March 2022 Cardiovascular: revenue $139.5mn, down 10.8% YOY 2021A Financials • DES volume: 1.22mn units (+132% YOY) CRM & Ortho Int'l 14.5%YOY • Balloon & accessories revenue: +47.5% YOY Revenue • OCT & DSA successfully la
Slide 7: Global business developed rapidly through great strategic layout
2021 Annual Results Global business developed rapidly through great strategic layout 31 March 2022 Overseas Revenue Growth 80+ 20,000+ 6,800+ • Overall: South America +29.9%, EMEA +16.8%, North America +6.7% Countries & Regions Hospitals Patents (incl. applications) • Cardiovascular: EMEA +136%, Sou
Slide 8: Proactive engagement with global capital markets
2021 Annual Results Proactive engagement with global capital markets 31 March 2022 ~$1.57bn raised in total Feb 2021 Jun 2021 Jun 2021 Jul 2021 Heart Valve MPSC Electrophysiology1 CRM • Successful listing on HKEx (stock • Raised ~$689mn • Application accepted • Equity financing of $150mn code: 2160.
Slide 9: Enhance growth potential with strategic investment across the value chain
2021 Annual Results Enhance growth potential with strategic investment across the value chain 31 March 2022 Strategic collaboration with leading companies around the globe 1Q 2021 May 2021 Jul 2021 Aug 2021 Surgical Robot Neurovascular Heart Valve Electrophysiology1 • Established JVs with Robocath,
Slide 10: Distinguished product highlights and clinical progress
2021 Annual Results Distinguished product highlights and clinical progress 31 March 2022 26 Green Path products 7 FDA approvals & Domestic No.1 in industry for 7 consecutive years Overseas 15 CE marks newly obtained Cardio- • Firesorb® completed patient enrollment for FUTURE-III Pivotal Trial • Fire
Slide 11: Contents
Contents 1 Company Highlights 2 Business Review 3 Financial Review 4 Outlook 5 Appendix – Financial Statements
Slide 12: Cardiovascular business
2021 Annual Results Cardiovascular business 31 March 2022 Business Highlights DES DES Sales Volume DES Overseas Revenue1 21A revenue $93.1mn Units ’000 USD: million Covering 2,900+ hospitals, newly penetrated ~610 hospitals Top 1 China +132% +39.3% Domestic First DSA system Soul-Man™ obtained NMPA &
Slide 13: CRM business
2021 Annual Results CRM business 31 March 2022 Non-China Business Highlights China Business Highlights Non-China Revenue China Revenue USD: million +17.2% USD: million Top 1 One of the +53.7% Chinese player 172.2 206.8 only 5 8.1 13.6 No. 1 multi-national players market share for China-made products
Slide 14: Endovascular business
2021 Annual Results Endovascular business 31 March 2022 Business Highlights Product Pre-clinical Clinical Registration Key Financials Talos® Thoracic USD: million Stent Graft NMPA approved in Jan-2022 +45.6% System Aortics 2020 +45.2% Stents 106.0 +46.1% 2021 Branched Aortics • Design validation 6
Slide 15: Neurovascular business
2021 Annual Results Neurovascular business 31 March 2022 Business Highlights Product Pre-clinical Clinical Registration Revenue Revenue Breakdown by Product Type NUMEN Silk™ 3D Electro- • 2nd generation of NUMEN coil family nically Detachable Coil NMPA approved in Feb-2022 USD: million USD: millio
Slide 16: Heart valve business
2021 Annual Results Heart valve business 31 March 2022 Financial Highlights Business Highlights Market strategy & Hospital Coverage Key Financials Gross Profit Margin USD: million +93.2% +15.4ppts +161.6% Domestic: 2020 VitaFlow Liberty™ launched in Sep., accounting for ~60% of the total implantatio
Slide 17: Heart valve business (cont'd)
Heart valve business (cont’d) 2021 Annual Results 31 March 2022 Product Pre-clinical Clinical Registration NMPA approved in Aug 2021 VitaFlow Liberty™ • Submitted for CE in Dec 2021 TAVI • Design fixing VitaFlow® III (aortic valve) VitaFlow® Balloon Expandable • Design stage In-house Developed Rep
Slide 18: Surgical robot business
2021 Annual Results Surgical robot business 31 March 2022 POS Product Pre-clinical Clinical Registration IPO 收单业务 Obtained NMPA approval in Jan-22 Toumai® Laparoscopic IPO on HKEx on Nov 2, 2021 Surgical Robot Laparoscopic • First surgical robot company listing on HKEx • Selected for inclusion in
Slide 19: Orthopedics business
2021 Annual Results Orthopedics business 31 March 2022 Non-China Business Highlights China Business Highlights Revenue Revenue Breakdown by Region Revenue Spine & Trauma USD: million USD: million +11.8% +47.4% EMEA 27% Revenue Growth 29.9 193.3 EMEA: +27.6% 22.4 5.5 171.7 US 45% 21A Japan: +6.7% 3.7
Slide 20: Build a true medical ecosystem to reshape and prolong life for everyone
2021 Annual Results Build a true medical ecosystem to reshape and prolong life for everyone 31 March 2022 Natural Orifice Intervention Rehabilitation Endocrinology ENT, Ophthalmology & Dental Skin & Body Management • Provide solutions to urinary, • Focus on muscle & bone • Core platform: micro-infus
Slide 21: Contents
Contents 1 Company Highlights 2 Business Review 3 Financial Review 4 Outlook 5 Appendix – Financial Statements
Slide 22: Consolidated financial performance
2021 Annual Results Consolidated financial performance 31 March 2022 Revenue Gross Profit Margin USD: million +15.0% 778.6 67.2% 63.2% 648.7 2020 2021 2020 2021 Operating Expenses Net (Loss)/Profit Attributable to Equity Shareholders USD: million USD: million -191.3 845.3 -276.5 616.8 2020 2021 2020
Slide 23: Operating expenses
2021 Annual Results Operating expenses 31 March 2022 Sales & Marketing Expenses Administrative Expenses R&D Expenses USD: million USD: million USD: million 400 40.0% 350 45.0% 400.0 50.0% 38.2% 40.0% 45.0% 350 32.1% 35.0% 300 350.0 39.2% 38.2% 35.0% 40.0% 300 30.0% 29.7% 26.2% 250 35.0% 30.0% 300.0
Slide 24: Contents
Contents 1 Company Highlights 2 Business Review 3 Financial Review 4 Outlook 5 Appendix – Financial Statements
Slide 25: Innovative product pipeline fueling long-term growth
Innovative product pipeline fueling long-term growth Firesorb® Rapamycin Coronary Rotational Intravascular Firehawk® Coronary Stent Graft Firefighter™ Cardio- Bioresorbable Drug-coated Atherectomy Firehawk® Lithotripsy Plus System Pro/NC Pro vascular Scaffolds Balloon System FDA Balloon NMPA&CE NMPA
Slide 26: Contents
Contents 1 Company Highlights 2 Business Review 3 Financial Review 4 Outlook 5 Appendix – Financial Statements
Slide 27: Appendix I - Consolidated Income Statement
Appendix I - Consolidated Income Statement USD'000 2021 2020 Var. Revenue 778,639 648,732 20.0% Cost of sales (286,866) (212,700) 34.9% Gross profit 491,773 436,032 12.8% Other net income 76,475 32,924 132.3% Research and development costs (297,778) (192,629) 54.6% Distribution cost (297,532) (254,1
Slide 28: Appendix II - Consolidated Balance Sheet
Appendix II - Consolidated Balance Sheet USD'000 31 Dec 2021 31 Dec 2020 Var. Non-current assets Investment properties 7,407 5,284 40% Other property, plant and equipment 922,874 481,203 92% Intangible assets 256,609 138,397 85% Prepayments for non-current assets 18,159 7,724 135% Goodwill 290,565 1
Slide 29: Appendix II - Consolidated Balance Sheet
Appendix II - Consolidated Balance Sheet USD'000 31 Dec 2021 31 Dec 2020 Var. Non-current liablities Interest-bearing borrowings 269,637 181,988 48% Lease liabilities 168,437 42,774 294% Deferred income 35,098 37,844 -7% Convertible bonds 660,369 48,583 1259% Contract liabilities 26,243 29,855 -12%
Slide 30: Disclaimer
2021 Annual Results Disclaimer 31 March 2022 This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no pa